Clinical Trial Update: Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of APL-1202 in patients with non-muscle invasive bladder cancer resistant to one induction course of BCG treatment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• APL-1202 (APL-1202)

Snippet

Sponsor: Asieris Pharmaceutical Technologies Co., Ltd. | Conditions: Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 1, Phase 2 | Status: COMPLETED